Stefani Spranger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefani Spranger has a total of 366 co-authors. Here are the top co-authors by number of shared publications:
- Forest M. White
Department of Biological Engineering, Massachusetts Institute of Technology
33 shared publications - Darrell J. Irvine
The Scripps Research Institute
32 shared publications - Ellen Duong
Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts
32 shared publications - Elen Torres-Mejia
Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts
31 shared publications - Kim Bich Nguyen
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
31 shared publications - Leon Yim
Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts
31 shared publications
Latest Publications
- Open Access
Radiation therapy synergizes with mRNA vaccination to overcome microglia-mediated suppression of dendritic cell migration and T cell priming in glioblastoma
Glioblastomas (GBMs) are uniformly fatal brain tumors resistant to immunotherapy, yet the mechanisms driving immune dysfunction remain poorly understood. Here we identify a tissue-specific mechanism of dendritic cell (DC) dysfunction contributing to GBM immune evasion. We demonstrate that while systemic immunity depends on type 1 conventional DCs (cDC1s), GBMs preferentially accumulate cDC2s with impaired antigen-presenting capacity. Further, microglia-derived GAS6 and PROS1 signaling through the AXL receptor on DCs suppresses DC activation and, critically, migration to tumor-draining lymph nodes. Pharmacologic AXL inhibition enhances DC migration and consequently anti-tumor immunity. Importantly, radiation therapy activates cDC1-mediated endogenous immune responses, which synergizes with mRNA vaccination to promote complete and durable immune-mediated tumor regression. These findings establish DC-mediated immunity as a therapeutic target in brain tumors and reveal a synergistic mechanism for combining radiation with personalized cancer vaccines. Highlights: ● The GBM TME is dominated by cDC2 responses, with poor accumulation of cDC1s and blunted systemic antitumor immunity ● Microglia suppress cDC migration and activation in the CNS via AXL signaling, and AXL blockade restores DC activation and migration ● Radiation therapy reactivates cDC1-mediated endogenous immunity against GBM ● Radiation therapy and tumor antigen-targeting mRNA vaccination achieve durable tumor cures in orthotopic and autochthonous GBM models
Open AccessRadiation therapy synergizes with mRNA vaccination to overcome microglia-mediated suppression of dendritic cell migration and T cell priming in glioblastoma
Glioblastomas (GBMs) are uniformly fatal brain tumors resistant to immunotherapy, yet the mechanisms driving immune dysfunction remain poorly understood. Here we identify a tissue-specific mechanism of dendritic cell (DC) dysfunction contributing to GBM immune evasion. We demonstrate that while systemic immunity depends on type 1 conventional DCs (cDC1s), GBMs preferentially accumulate cDC2s with impaired antigen-presenting capacity. Further, microglia-derived GAS6 and PROS1 signaling through the AXL receptor on DCs suppresses DC activation and, critically, migration to tumor-draining lymph nodes. Pharmacologic AXL inhibition enhances DC migration and consequently anti-tumor immunity. Importantly, radiation therapy activates cDC1-mediated endogenous immune responses, which synergizes with mRNA vaccination to promote complete and durable immune-mediated tumor regression. These findings establish DC-mediated immunity as a therapeutic target in brain tumors and reveal a synergistic mechanism for combining radiation with personalized cancer vaccines. Highlights: ● The GBM TME is dominated by cDC2 responses, with poor accumulation of cDC1s and blunted systemic antitumor immunity ● Microglia suppress cDC migration and activation in the CNS via AXL signaling, and AXL blockade restores DC activation and migration ● Radiation therapy reactivates cDC1-mediated endogenous immunity against GBM ● Radiation therapy and tumor antigen-targeting mRNA vaccination achieve durable tumor cures in orthotopic and autochthonous GBM models
- Open Access
Modeling lung adenocarcinoma using layer-by-layer nanoparticles mitigates innate immune cell activation
Lung adenocarcinoma, driven frequently by KRAS and p53 mutations, remains a leading cause of cancer mortality. Current state-of-the-art genetically engineered mouse models often rely on viral delivery of recombinases, such as Cre recombinase, to initiate transformation. However, viral particles can infect and activate innate immune cells, thus potentially impacting studies of tumor-immune dynamics. Here, we develop a layer-by-layer (LbL) polyplex platform using poly(β-aminoester) (PBAE) polymers layered with poly-L-aspartic acid (PLD) to deliver Cre mRNA to lungs while avoiding immune cell transfection and activation. PLD-coated nanoparticles (PLD-NPs) exhibit stable mRNA encapsulation and efficient transfection in vitro, even after lyophilization and long-term storage. In Kras LSL-G12D/+ ;p53 flox/flox (KP) mice, PLD-NPs initiate lung adenocarcinomas that mirror human histopathology without infecting or activating dendritic cells and alveolar macrophages, unlike lentiviral (LV) or adenoviral delivery methods. Single-cell transcriptional profiling revealed that LV administration drives long-term upregulation of antigen presentation and costimulatory machinery in lung-resident myeloid populations. This persistent immune activation is avoided by NP delivery. By uncoupling tumor initiation from innate immune activation, this platform enables the high-fidelity interrogation of tumor-immune dynamics, especially for non-inflammation-driven lung cancer.
Open AccessModeling lung adenocarcinoma using layer-by-layer nanoparticles mitigates innate immune cell activation
Lung adenocarcinoma, driven frequently by KRAS and p53 mutations, remains a leading cause of cancer mortality. Current state-of-the-art genetically engineered mouse models often rely on viral delivery of recombinases, such as Cre recombinase, to initiate transformation. However, viral particles can infect and activate innate immune cells, thus potentially impacting studies of tumor-immune dynamics. Here, we develop a layer-by-layer (LbL) polyplex platform using poly(β-aminoester) (PBAE) polymers layered with poly-L-aspartic acid (PLD) to deliver Cre mRNA to lungs while avoiding immune cell transfection and activation. PLD-coated nanoparticles (PLD-NPs) exhibit stable mRNA encapsulation and efficient transfection in vitro, even after lyophilization and long-term storage. In Kras LSL-G12D/+ ;p53 flox/flox (KP) mice, PLD-NPs initiate lung adenocarcinomas that mirror human histopathology without infecting or activating dendritic cells and alveolar macrophages, unlike lentiviral (LV) or adenoviral delivery methods. Single-cell transcriptional profiling revealed that LV administration drives long-term upregulation of antigen presentation and costimulatory machinery in lung-resident myeloid populations. This persistent immune activation is avoided by NP delivery. By uncoupling tumor initiation from innate immune activation, this platform enables the high-fidelity interrogation of tumor-immune dynamics, especially for non-inflammation-driven lung cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S1 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S1 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S3 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S3 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S4 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S4 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion